ID
36076
Description
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT02422199
Link
https://clinicaltrials.gov/show/NCT02422199
Keywords
Versions (1)
- 4/14/19 4/14/19 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
April 14, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
lapatinib | neratinib | pyrotinib | HER2 Targeted Tyrosine kinase inhibitor
Data type
boolean
Alias
- UMLS CUI [1]
- C1506770
- UMLS CUI [2]
- C2713008
- UMLS CUI [3]
- C3828434
- UMLS CUI [4,1]
- C0069515
- UMLS CUI [4,2]
- C1521840
- UMLS CUI [4,3]
- C1268567
Description
capecitabine
Data type
boolean
Alias
- UMLS CUI [1]
- C0671970
Similar models
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
- StudyEvent: Eligibility
C1265611 (UMLS CUI [1,2])
C2348909 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C1514873 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201899 (UMLS CUI [2])
C0005845 (UMLS CUI [3])
C0373595 (UMLS CUI [4])
C0428772 (UMLS CUI [5])
C1882513 (UMLS CUI [6])
C0079399 (UMLS CUI [7])
C2713008 (UMLS CUI [2])
C3828434 (UMLS CUI [3])
C0069515 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C1268567 (UMLS CUI [4,3])